 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...496497498499500501502503504505506...507508» |
- bortezomib / Generic mfg.
Enrollment open, Combination therapy: Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 10, 2013
P2, N=17, Recruiting, Sponsor: Stanford University
Not yet recruiting --> Recruiting
- cixutumumab (IMC A12) / Eli Lilly
Enrollment closed, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 10, 2013
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Herceptin (trastuzumab) / Roche
Trial completion: Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer (clinicaltrials.gov) - Mar 5, 2013
P2, N=95, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
New P2 trial: Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL (clinicaltrials.gov) - Mar 3, 2013
P2, N=196, Recruiting, Sponsor: Fudan University
- Enrollment open, Metastases: ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer (clinicaltrials.gov) - Mar 3, 2013
P2, N=56, Recruiting, Sponsor: Susanne Crocamo
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
Enrollment open: CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma (clinicaltrials.gov) - Feb 25, 2013
P2, N=24, Recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- NOV-002 / Cellectar
Enrollment change, Combination therapy: NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer (clinicaltrials.gov) - Feb 19, 2013
P2, N=41, Completed, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Not yet recruiting --> Recruiting N=23 --> 41
- || Istodax (romidepsin) / Astellas, BMS
New P3 trial: Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Feb 19, 2013
P3, N=420, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, BRCA Biomarker: Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (clinicaltrials.gov) - Feb 19, 2013
P2, N=30, Recruiting, Sponsor: Dana-Farber Cancer Institute
- || New P3 trial: A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients (clinicaltrials.gov) - Feb 14, 2013
P3, N=732, Recruiting, Sponsor: Sun Yat-sen University
- albumin-bound paclitaxel / Generic mfg.
Trial completion: Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer (clinicaltrials.gov) - Feb 14, 2013
P=N/A, N=66, Completed, Sponsor: Harold J. Burstein, MD, PhD
N=23 --> 41 Active, not recruiting --> Completed
- Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Trial completion: Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer (clinicaltrials.gov) - Feb 14, 2013
P2, N=109, Completed, Sponsor: Harold J. Burstein, MD, PhD
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Herceptin (trastuzumab) / Roche
Trial completion: Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer (clinicaltrials.gov) - Feb 14, 2013
P2, N=41, Completed, Sponsor: Harold J. Burstein, MD, PhD
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Rituxan (rituximab) / Roche
Enrollment change: NCI-2018-01851: Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma (clinicaltrials.gov) - Feb 13, 2013
P1, N=110, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=90 --> 110
- | bortezomib / Generic mfg.
Enrollment change, Metastases: Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL (clinicaltrials.gov) - Feb 11, 2013
P1/2, N=49, Completed, Sponsor: Asan Medical Center
N=90 --> 110 N=63 --> 49
- | bortezomib / Generic mfg.
Trial completion, Metastases: Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL (clinicaltrials.gov) - Feb 11, 2013
P1/2, N=49, Completed, Sponsor: Asan Medical Center
N=63 --> 49 Recruiting --> Completed
- Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Enrollment change, Surgery: Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Feb 10, 2013
P2, N=445, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=362 --> 445
- || cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New P3 trial: A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients (clinicaltrials.gov) - Feb 7, 2013
P3, N=380, Recruiting, Sponsor: Sun Yat-sen University
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Roche
New P2 trial: Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma (clinicaltrials.gov) - Feb 3, 2013
P2, N=155, Recruiting, Sponsor: St. Jude Children's Research Hospital
- Cynviloq (paclitaxel polymeric micelle formulation) / Sorrento, Samyang Group, ImmunityBio
New P2 trial, Metastases: A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer (clinicaltrials.gov) - Feb 3, 2013
P2, N=48, Recruiting, Sponsor: Gachon University Gil Medical Center
- | Enrollment closed: PETAL: Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Feb 3, 2013
P3, N=696, Active, not recruiting, Sponsor: University Hospital, Essen
N=362 --> 445 Recruiting --> Active, not recruiting
- ||||| Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial initiation date, Metastases: IXAMPLE2: A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer (clinicaltrials.gov) - Jan 31, 2013
P3, N=500, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Initiation date: Jan 1996 --> Aug 2009
- || brivanib alaninate (BMS-582664) / ZAI Lab
Trial initiation date, Combination therapy, Metastases: Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers (clinicaltrials.gov) - Jan 31, 2013
P1, N=189, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 1996 --> Aug 2009 Initiation date: Nov 2001 --> Mar 2009
- |||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jan 31, 2013
P2, N=164, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Initiation date: Nov 2001 --> Mar 2009 Active, not recruiting --> Completed
- doxorubicin hydrochloride / Generic mfg.
Trial completion: Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma (clinicaltrials.gov) - Jan 28, 2013
P2, N=45, Completed, Sponsor: European Lung Cancer Working Party
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Herceptin (trastuzumab) / Roche
New P2 trial, Tumor cell: Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells (clinicaltrials.gov) - Jan 27, 2013
P2, N=50, Recruiting, Sponsor: Washington University School of Medicine
- ||||| Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment closed, Metastases: NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed (clinicaltrials.gov) - Jan 27, 2013
P3, N=390, Active, not recruiting, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P3 trial: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas (clinicaltrials.gov) - Jan 24, 2013
P3, N=300, Recruiting, Sponsor: Seattle Genetics, Inc.
- lenalidomide / Generic mfg., doxorubicin hydrochloride / Generic mfg., vinblastine / Generic mfg.
Enrollment closed, Metastases: AVD-Rev: Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients (clinicaltrials.gov) - Jan 24, 2013
P1, N=30, Active, not recruiting, Sponsor: University of Cologne
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Trial completion, Surgery: Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Jan 24, 2013
P2, N=39, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Xalkori (crizotinib) / Pfizer
Trial initiation date, Combination therapy: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Jan 23, 2013
P1, N=58, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Initiation date: Jul 2012 --> Mar 2013
- | Matulane (procarbazine hydrochloride) / Leadiant Biosci
New P2 trial: Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 23, 2013
P2, N=90, Not yet recruiting, Sponsor: AIDS Malignancy Clinical Trials Consortium
- ||| Lartruvo (olaratumab) / Eli Lilly
Enrollment closed, Metastases: A Study of Olaratumab in Soft Tissue Sarcoma (clinicaltrials.gov) - Jan 23, 2013
P1/2, N=146, Active, not recruiting, Sponsor: Eli Lilly and Company
Initiation date: Jul 2012 --> Mar 2013 Recruiting --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Combination therapy: Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 23, 2013
P2, N=14, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment change: Chemotherapeutic Agents in Brain/Breast (clinicaltrials.gov) - Jan 22, 2013
P=N/A, N=10, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Completed N=71 --> 10
- bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: Bortezomib-Dexamethasone-Doxorubicin-Study (clinicaltrials.gov) - Jan 22, 2013
P2, N=72, Completed, Sponsor: Austrian Forum Against Cancer
N=71 --> 10 N=40 --> 72
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL (clinicaltrials.gov) - Jan 21, 2013
P2, N=23, Recruiting, Sponsor: Asan Medical Center
N=40 --> 72 N=32 --> 23
- | Beleodaq (belinostat) / Aurobindo, Assertio
Enrollment change, Combination therapy: A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Jan 21, 2013
P1/2, N=47, Completed, Sponsor: TopoTarget A/S
N=32 --> 23 N=65 --> 47
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Enrollment closed: ALL Adult Consortium Trial: Adult ALL Trial (clinicaltrials.gov) - Jan 21, 2013
P2, N=112, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
N=65 --> 47 Recruiting --> Active, not recruiting
- | Beleodaq (belinostat) / Aurobindo, Spectrum Pharma
Trial completion, Combination therapy: A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Jan 21, 2013
P1/2, N=47, Completed, Sponsor: TopoTarget A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tomudex (raltitrexed) / Pfizer, AstraZeneca
Enrollment open, Metastases: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic (clinicaltrials.gov) - Jan 20, 2013
P2, N=80, Recruiting, Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Zolinza (vorinostat) / Merck (MSD)
Enrollment change: SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 17, 2013
P1/2, N=14, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=52 --> 14
- Enrollment closed, Metastases: Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Jan 17, 2013
P2, N=53, Active, not recruiting, Sponsor: Washington University School of Medicine
N=52 --> 14 Recruiting --> Active, not recruiting
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion: SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 17, 2013
P1/2, N=14, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Ontak (denileukin diftitox) / Eisai, TSD Japan
Trial withdrawal: Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 16, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Active, not recruiting --> Completed Completed --> Withdrawn
- Ontak (denileukin diftitox) / Eisai, TSD Japan
Enrollment change: Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 16, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Completed --> Withdrawn N=15 --> 0
- Herceptin (trastuzumab) / Roche
Clinical: Kinetics of Troponin and BNP in Breast Cancer Chemotherapy With Adriamycin and Trastuzumab (clinicaltrials.gov) - Jan 16, 2013
P=N/A, N=20, Enrolling by invitation, Sponsor: Mayo Clinic
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P1/2 trial: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma (clinicaltrials.gov) - Jan 16, 2013
P1/2, N=51, Recruiting, Sponsor: National Cancer Institute (NCI)
- bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change, Metastases: Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer (clinicaltrials.gov) - Jan 15, 2013
P2, N=4, Terminated, Sponsor: University of Wisconsin, Madison
N=15 --> 0 N=54 --> 4
- Herceptin (trastuzumab) / Roche
Trial termination, Surgery, Metastases: Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer (clinicaltrials.gov) - Jan 14, 2013
P3, N=396, Terminated, Sponsor: National Cancer Institute (NCI)
N=54 --> 4 Completed --> Terminated; Administratively complete.